XPO1/CRM1-SELECTIVE INHIBITORS OF NUCLEAR EXPORT (SINE) REDUCE TUMOR SPREADING AND IMPROVE OVERALL SURVIVAL IN PRECLINICAL MODELS OF PROSTATE CANCER (PCa).